BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 33652134)

  • 1. Controversies in Allergy: A Pro/Con Review of Sublingual Allergen Immunotherapy and Allergic Asthma.
    Calderón MA; Bacharier LB
    J Allergy Clin Immunol Pract; 2021 May; 9(5):1818-1825. PubMed ID: 33652134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Subcutaneous and Sublingual Immunotherapy for House Dust Mite Allergy: A Network Meta-Analysis-Based Comparison.
    Kim JY; Jang MJ; Kim DY; Park SW; Han DH
    J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4450-4458.e6. PubMed ID: 34464748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
    Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
    JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma.
    Richards JR; Stumpf JL
    Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
    Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
    Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma.
    Agache I; Lau S; Akdis CA; Smolinska S; Bonini M; Cavkaytar O; Flood B; Gajdanowicz P; Izuhara K; Kalayci O; Mosges R; Palomares O; Papadopoulos NG; Sokolowska M; Angier E; Fernandez-Rivas M; Pajno G; Pfaar O; Roberts GC; Ryan D; Sturm GJ; van Ree R; Varga EM; van Wijk RG; Yepes-Nuñez JJ; Jutel M
    Allergy; 2019 May; 74(5):855-873. PubMed ID: 31095767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials.
    Tao L; Shi B; Shi G; Wan H
    Clin Respir J; 2014 Apr; 8(2):192-205. PubMed ID: 24118881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.
    Canonica GW; Virchow JC; Zieglmayer P; Ljørring C; Smith IM; Mosbech H
    Expert Rev Clin Immunol; 2016 Aug; 12(8):805-15. PubMed ID: 27322777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases.
    Nolte H; Maloney J
    Allergol Int; 2018 Jul; 67(3):301-308. PubMed ID: 29759659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
    Hesse L; Nawijn MC
    Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for house-dust mite allergy.
    Nelson HS
    Allergy Asthma Proc; 2018 Jul; 39(4):264-272. PubMed ID: 30095391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
    Hesse L; Petersen AH; Nawijn MC
    Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention Is Better than Cure: Impact of Allergen Immunotherapy on the Progression of Airway Disease.
    Arshad H; Lack G; Durham SR; Penagos M; Larenas-Linnemann D; Halken S
    J Allergy Clin Immunol Pract; 2024 Jan; 12(1):45-56. PubMed ID: 37844847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms.
    Yepes-Nuñez JJ; Guyatt GH; Gómez-Escobar LG; Pérez-Herrera LC; Chu AWL; Ceccaci R; Acosta-Madiedo AS; Wen A; Moreno-López S; MacDonald M; Barrios M; Chu X; Islam N; Gao Y; Wong MM; Couban R; Garcia E; Chapman E; Oykhman P; Chen L; Winders T; Asiniwasis RN; Boguniewicz M; De Benedetto A; Ellison K; Frazier WT; Greenhawt M; Huynh J; Kim E; LeBovidge J; Lind ML; Lio P; Martin SA; O'Brien M; Ong PY; Silverberg JI; Spergel J; Wang J; Wheeler KE; Schneider L; Chu DK
    J Allergy Clin Immunol; 2023 Jan; 151(1):147-158. PubMed ID: 36191689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial.
    Mosbech H; Deckelmann R; de Blay F; Pastorello EA; Trebas-Pietras E; Andres LP; Malcus I; Ljørring C; Canonica GW
    J Allergy Clin Immunol; 2014 Sep; 134(3):568-575.e7. PubMed ID: 24797423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.